证券代码：301239 证券简称：普瑞眼科 公告编号：2025-031 成都普瑞眼科医院集团股份有限公司 关于实际控制人部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、股东股份解除质押及累计质押的基本情况 2．股东股份累计质押情况 成都普瑞眼科医院集团股份有限公司（以下简称"公司"）近日接到实际 控制人徐旭阳先生的通知，获悉徐旭阳先生将其所持有的公司部分质押股份办 理了解除质押业务。具体事项如下： | 股东 | 是否为控股 股东或第一 | 本次解除 | 占其所 | 占公司 | 质押起始 | 质押解除 | 质权 | | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 大股东及其 | 质押数量 | 持股份 | 总股本 | 日 | 日 | 人 | | | 一致行动人 | （股） | 比例 | 比例 | | | | | | 是 | 3,900,000 | 38.61% | 2.61% | 2023年8月 30日 | 2025年6月 | 云南 | | | | 400,000 | 3 ...

Group 1 - The core viewpoint is that the pharmaceutical sector is gradually recovering, reflected in the performance of listed companies, despite limited overall index growth [1] - The manager emphasizes a balanced approach to investment, focusing on risk-reward ratios and aiming for excess returns relative to the pharmaceutical index over time [1] - The fund manager has a strong track record, with the fund achieving a return of 87.60% since inception, ranking first in its category for various time frames [1] Group 2 - The fund's investment scope includes various segments of the pharmaceutical and healthcare industry, such as chemical pharmaceuticals, traditional Chinese medicine, biological products, and medical services [2] - The top ten holdings of the fund are diversified across high-growth areas like innovative drugs and medical devices, which helps mitigate individual stock volatility while participating in overall industry growth [2] - The holdings are balanced, reducing the risk associated with any single stock and enhancing exposure to the sector's growth potential [2]

1．本次股东大会不存在否决议案的情形； 2．本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席的情况 （一）会议召开情况 证券代码：301239 证券简称：普瑞眼科 公告编号：2025-030 成都普瑞眼科医院集团股份有限公司 2024年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 3．会议召开的方式：本次股东大会采用现场投票与网络投票相结合的方式 召开。 4．会议召集人：成都普瑞眼科医院集团股份有限公司（以下简称"公司"） 董事会。 5．会议主持人：公司董事长徐旭阳先生。 1．会议召开时间 6．本次股东大会的召集和召开程序符合有关法律、法规、规范性文件及 《公司章程》的有关规定。 （1）现场会议时间：2025年5月20日（星期二）15:00； （二）会议出席情况 （2）网络投票时间 其中，通过深圳证券交易所交易系统进行网络投票的时间为：2025年5月20 日9:15-9:25、9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系 统进行网络投票的时间为：2025年5月20日9:15- ...

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于成都普瑞眼科医院集团股份有限公司 2024 年年度股东大会的 法律意见书 国枫律股字[2024]A0248 号 致：成都普瑞眼科医院集团股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见 证贵公司 2024 年年度股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称 "《股东会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证券法律 业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简称"《证券法 律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《成都普瑞眼科医院 集团股份有限公司章程》（以下简称"《公司章程》"）的规定，就本次会议的召集与召开 程序、召集人资格、出席会议人员资格、会议表决程序及表决结果等 ...

Industry Outlook - The ophthalmology medical service industry faces both opportunities and challenges, with a growing market size driven by an aging population and increasing demand for myopia prevention [2] - The market for cataract surgeries is expected to expand, while the refractive surgery market has significant growth potential due to low penetration rates [2] - National policies supporting private healthcare provide a favorable environment for the development of private ophthalmology hospitals [2] Current Market Performance - In 2024, the ophthalmology industry experienced a slowdown in growth due to intense domestic competition, low consumer demand, and policy impacts such as healthcare payment reforms [3] - Larger companies showed better profit resilience amidst these challenges, indicating a trend towards increasing market concentration [3] Company Performance - In Q1 2025, the company reported total revenue of CNY 742 million, a year-on-year increase of 9.82%, and a net profit of CNY 27 million, up 61.18% [4][7] - The company has effectively controlled costs and optimized its business structure through the introduction of new technologies [4] Future Growth Drivers - Future profit growth for the company is driven by six key factors: 1. Aging population and increased awareness of eye health driving demand for cataract and vision care services 2. Business structure optimization and promotion of high-end cataract projects to enhance profit margins 3. Introduction of advanced technologies to improve service attractiveness and gross margins 4. Gradual reduction of losses from newly opened hospitals, enhancing performance flexibility 5. Cost control through centralized procurement and digital management to improve operational efficiency 6. A strategic approach to investment expansion under a "national chain + local integration" model [5]

证券代码：301239 证券简称：普瑞眼科 公告编号：2025-029 成都普瑞眼科医院集团股份有限公司 关于控股股东部分股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、股东股份质押的基本情况 注：（1）上表中"占其所持股份比例"的合计数为本次质押后累计质押股份总数占控 股股东及其一致行动人所持有公司股份总数的比例； （2）浦视玖昊指上海浦视玖昊企业管理合伙企业（有限合伙）；浦视捌昊指上海 浦视捌昊企业管理合伙企业（有限合伙）；浦视伍昊指上海浦视伍昊企业管理合伙企 业（有限合伙）；浦视叁昊指上海浦视叁昊企业管理合伙企业（有限合伙）； （3）本公告中出现总数与各分项数值之和尾数不符的情况，均为四舍五入原因造 成。 二、其他说明 截至公告披露日，上述股东及其一致行动人所持质押股份情况如下： 股 东 名 称 持股数 量 （股） 持 股 比 例 本次质 押前质 押股份 数量 （股） 本次质 押后质 押股份 数量 （股） 占 其 所 持 股 份 比 例 占 公 司 总 股 本 比 例 已质押股份 情况 未质押股份 情况 已质押 股份限 售和冻 结数量 ...

Core Viewpoint - Chengdu Puri Eye Hospital Group Co., Ltd. is a leading provider of comprehensive eye care services in China, focusing on innovation and professional expertise to build a competitive advantage in the ophthalmology sector [2]. Group 1: Company Overview - The company specializes in diagnosing, treating, and providing healthcare services for various eye diseases, including refractive surgery, cataracts, and other ophthalmic conditions [2]. - Puri Eye has established a strong brand identity based on "professionalism, innovation, and responsibility," and has created a competitive edge through a nationwide chain of eye hospitals [2]. - The company employs a "full-cycle eye health management" approach, integrating renowned medical experts and cutting-edge technology to enhance service quality [2]. Group 2: Financial Performance - In the first quarter of 2025, the company reported a revenue of 742 million yuan, representing a year-on-year increase of 9.82% [3]. - The net profit for the same period was approximately 27.28 million yuan, showing a significant year-on-year growth of 61.18% [3]. - The gross profit margin stood at 39.34%, indicating a healthy profitability level compared to industry peers [3]. Group 3: Market Position - As of the latest data, Puri Eye's market capitalization is approximately 6.178 billion yuan, with a price-to-earnings (PE) ratio of 67.51 [3]. - The company has a price-to-book (PB) ratio of 2.89, which is competitive within the industry [3]. - The company is positioned favorably against industry averages, with its PE and PB ratios reflecting strong market confidence [3].

普瑞眼科2025年第一季度报告显示，普瑞眼科报告期内营业总收入为7.42亿元，同比增长9.82%；归属 于上市公司股东的净利润为2727.94万元，同比增长61.18%；归属于上市公司股东的扣除非经常性损益 的净利润为2831.55万元，同比增长48.37%；经营活动产生的现金流量净额为1.95亿元。 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | | --- | --- | --- | --- | --- | | | | | (%) | | | 营业收入(元) | 742. 251. 316. 24 | 675,882,973,16 | | 9.82% | | 归属于上市公司股东的净利 | 27, 279, 356. 63 | 16, 924, 936, 43 | | 61. 18% | | 润(元) | | | | | | 归属于上市公司股东的扣除 非经常性损益的净利润 | 28, 315, 487, 26 | 19,084,077.60 | | 48. 37% | | (元) | | | | | | 经营活动产生的现金流量净 额(元) | 194. 676. 885. 40 | 12 ...

Industry Rating - The industry investment rating is maintained at "Outperform the Market" [1] Core Insights - The medical services sector is under pressure in 2024 due to high base effects, but macroeconomic improvements are expected to drive a sustained recovery [2][5] - In Q1 2025, the demand for medical services has stabilized, leading to continuous profit improvement [3][5] - The gross profit margin has slightly declined, with 2024's margin at 37.02%, down 1.24 percentage points, and Q1 2025's margin at 36.14% [4][9] Summary by Sections 2024 Performance - The overall revenue for the medical services sector in 2024 is projected at 73.908 billion yuan, a year-on-year increase of 1.29% - The net profit attributable to shareholders is expected to be 4.857 billion yuan, a decrease of 16.37% - The net profit excluding non-recurring items is forecasted at 4.229 billion yuan, down 22.95% [2][9] Q1 2025 Performance - The total revenue for the medical services sector in Q1 2025 is 18.005 billion yuan, reflecting a year-on-year growth of 2.48% - The net profit attributable to shareholders is 1.325 billion yuan, showing a year-on-year increase of 16.24% - The net profit excluding non-recurring items is 1.266 billion yuan, up 18.21% [3][9] Profitability Metrics - The gross profit margin for 2024 is 37.02%, with a slight decline to 36.14% in Q1 2025 - The operating cash flow for Q1 2025 is 2.332 billion yuan, with a cash flow to net profit ratio of 158.22% [4][7]

为便于广大投资者更加全面深入地了解公司经营管理情况，公司定于2025 年5月19日（星期一）15:00-16:00在深圳证券交易所"互动易"平台"云访谈" 栏目举办2024年度网上业绩说明会，本次年度业绩说明会将采用网络远程的方 式举行，投资者可登陆深圳证券交易所"互动易"平台（irm.cninfo.com.cn）， 进入"云访谈"栏目参与本次业绩说明会。 公司拟出席本次业绩说明会的人员有：公司董事长徐旭阳先生、独立董事 邹欢先生、副总经理兼董事会秘书金亮先生、财务负责人杨国平先生、保荐代 表人李沁杭先生（如遇特殊情况，参会人员可能进行调整）。 为进一步做好中小投资者保护工作，增进投资者对公司的了解，现就公司 2024年度业绩说明会提前向投资者公开征集问题，广泛听取投资者的意见和建 议 ， 提 升 交 流 效率和 针 对 性 。 投 资 者 可 提 前 登 录 " 互 动 易 " 平 台 （irm.cninfo.com.cn）"云访谈"栏目进入公司本次业绩说明会页面进行提问。 公司将在2024年度业绩说明会上在信息披露允许范围内对投资者普遍关注的问 题进行回答。 本公司及董事会全体成员保证信息披露的内容真实、 ...